/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Lung Adenocarcinoma is an emerging landscape with 29 programs across 21 companies. The most active players are Lantern Pharma Inc.. 3 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
79%
Small molecule
22 of 28 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.
Analysis
95
clinical trials
Clinical Trials
95 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)